|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Supplementary Table 2. Comparison of clinical and biochemical characteristics and lung function in women with and without MAFLD and with and without NAFLD** | | | | | | | |
| **Characteristic** | **Non-MAFLD** | **MAFLD** | ***p*\*** | **Non-NAFLD** | **NAFLD** | ***p*\*\*** |
|  | **779 (80.6)** | **220 (19.4)** |  | **792 (82.7)** | **207 (17.3)** |  |
| Age, years | 66.79±7.519 | 65.58±7.30 | 0.038 | 65.97±7.73 | 64.39±7.72 | 0.006 |
| Ever-smoker | 943 (46.6) | 231 (44.6) | 0.220 | 312 (46.8) | 59 (43.8) | 0.322 |
| Alcohol intake | 116 (15.3) | 57 (26.2) | <0.001 | 126 (16.1) | 49 (23.6) | <0.001 |
| BMI, kg/m² | 22.86±2.69 | 27.41±2.79 | <0.001 | 23.63±2.75 | 27.66±2.63 | <0.001 |
| Waist circumference, cm | 81.71±8.61 | 92.67±9.61 | <0.001 | 84.63±8.75 | 93.30±11.36 | <0.001 |
| Systolic blood pressure, mmHg | 137.83±20.65 | 142.83±19.81 | <0.001 | 137.27±20.31 | 139.52±17.62 | 0.015 |
| Diastolic blood pressure, mmHg | 79.62±12.02 | 81.98±11.06 | <0.001 | 80.91±11.89 | 82.69±10.95 | 0.013 |
| Lung function tests |  |  |  |  |  |  |
| FVC, L | 2.10±0.52 | 2.01±0.49 | 0.016 | 2.11±0.49 | 2.07±0.61 | 0.524 |
| FVC, % of predicted value | 91.19±19.55 | 86.11±17.18 | <0.001 | 90.23±19.69 | 89.47±16.95 | 0.618 |
| FEV1, L | 1.76±0.44 | 1.65±0.41 | 0.001 | 1.75±0.41 | 1.72±0.44 | 0.423 |
| FEV1, % of predicted value | 89.59±19.78 | 83.11±16.42 | <0.001 | 88.48±19.78 | 86.28±17.14 | 0.278 |
| FEV1 /FVC, % | 84.22±7.98 | 83.07±9.51 | 0.072 | 84.19±8.24 | 83.05±8.74 | 0.082 |
| Comorbidities |  |  |  |  |  |  |
| COPD, % | 115 (14.4) | 36 (16.4) | 0.414 | 113 (14.3) | 31 (15.3) | 0.470 |
| Type 2 diabetes | 78 (10.0) | 64 (29.4) | <0.001 | 61 (7.7) | 47 (23.1) | <0.001 |
| Metabolic syndrome | 79 (10.6) | 88 (39.8) | <0.001 | 79 (10.3) | 74 (36.1) | <0.001 |
| Hypertension | 223 (30.0) | 68.2 (31.1) | 0.726 | 316 (40.1) | 95 (45.8) | 0.130 |
| Dyslipidemia | 230 (29.6) | 103 (47.2) | <0.001 | 283 (35.8) | 97 (47.2) | <0.001 |
| Laboratory tests |  |  |  |  |  |  |
| WBC count, 109/L | 5.91±1.51 | 6.28±1.52 | 0.003 | 5.93±1.64 | 6.23±1.41 | 0.013 |
| Hemoglobin, g/L | 131.99±16.37 | 135.08±11.01 | 0.001 | 131.32±16.3 | 135.01±10.83 | 0.002 |
| Platelet count, 109/L | 228.16±55.85 | 226.47±57.37 | 0.603 | 228.30±54.77 | 228.51±57.79 | 0.976 |
| FPG, mmol/L | 5.65±1.35 | 6.51±2.15 | <0.001 | 5.67±1.38 | 6.48±2.13 | <0.001 |
| ALT, U/L | 19.64±11.42 | 34.14±24.25 | <0.001 | 19.83±13.90 | 33.75±20.33 | <0.001 |
| AST, U/L | 25.22±14.19 | 28.49±15.12 | 0.012 | 25.52±16.17 | 27.15±12.40 | 0.169 |
| TC, mmol/L | 5.02±1.64 | 5.31±1.44 | 0.012 | 4.95±1.64 | 5.32±1.44 | 0.002 |
| TG, mmol/L | 1.72±1.03 | 2.34±1.59 | <0.001 | 1.74±1.04 | 2.29±1.70 | <0.001 |
| LDL, mmol/L | 3.12±0.99 | 3.36±1.05 | 0.005 | 3.36±0.99 | 3.11±1.08 | 0.004 |
| HDL, mmol/L | 1.47±0.41 | 1.30±0.34 | <0.001 | 1.46±0.409 | 1.36±0.39 | 0.003 |

\**p* non-MAFLD vs. MAFLD; *\*\*p* non-NAFLD vs. NAFLD. ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in the first second of exhalation; FVC, forced vital capacity; FPG, fasting plasma glucose; HDL, high-density lipoprotein cholesterol; LDL, low-density lipoprotein cholesterol; TC, total cholesterol; TG, triglycerides; NAFLD, nonalcoholic fatty liver disease; MAFLD, metabolic dysfunction-associated fatty liver disease; WBC, white blood cells.